Gastrointestinal stromal tumors: thirty years experience of an institution.

AIM To report our experience of gastrointestinal stromal tumors (GISTs) during the last 29 years. METHODS Thirty two cases of GIST referred to our Institution from the 1st January 1981 to the 10th June 2010 were reviewed. Metastases, recurrence and survival data were collected in relation to age, history, clinical presentation, location, size, resection margins and cellular features. RESULTS Mean age was 63.7 years (range, 40-90) and incidence was slightly higher in males (56%). R0 resection was performed in 90.7% of cases, R1 in 6.2% (2 cases) and R2 in 3.1% (one case). Using Fletcher's classification 8/32 (25%) had high risk, 9/32 (28%) intermediate and 15/32 (47%) low risk tumors. Follow-up varied from 1 mo to 29 years, with a median of 8 years; overall survival was 75% (24/32), disease-free survival was 72% and tumor-related mortality was 9.3%. Three patients with high risk GIST were treated with imatinib mesylate: one developed a recurrence after 36 mo, and 2 are free from disease at 41 mo. CONCLUSION Surgical treatment remains the gold standard therapy for resectable GISTs. Pathological and biological features of the neoplasm represent the most important factors predicting the prognosis.

[1]  Heikki Joensuu,et al.  Gastrointestinal stromal tumour , 2013, The Lancet.

[2]  C. Antonescu,et al.  Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial , 2009, The Lancet.

[3]  H. Gutman,et al.  Surgical management of gastrointestinal stromal tumors: Analysis of outcome with respect to surgical margins and technique , 2008, Journal of surgical oncology.

[4]  M. Kendrick,et al.  Laparoscopic gastric gastrointestinal stromal tumor resection: the mayo clinic experience. , 2008, Archives of surgery.

[5]  S. Parsons,et al.  Gastrointestinal stromal tumours (GIST) - 17 years experience from Mid Trent Region (United Kingdom). , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[6]  D. Bennett,et al.  Gastrointestinal stromal tumors (GIST) and laparoscopic resection , 2007, Surgical Endoscopy.

[7]  A. D. Van den Abbeele,et al.  NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

[8]  T. Nishida,et al.  Surgical strategy for gastric gastrointestinal stromal tumors: laparoscopic vs. open resection , 2007, Surgical Endoscopy.

[9]  M. Heinrich,et al.  Gastrointestinal stromal tumour , 2007, The Lancet.

[10]  M. Solej,et al.  Giant Gastrointestinal Stromal Tumor of the Stomach in An Elderly Patient , 2007, Journal of Gastrointestinal Surgery.

[11]  I. Cranshaw,et al.  Single center experience of laparoscopic vs. open resection for gastrointestinal stromal tumors of the stomach. , 2007, Hepato-gastroenterology.

[12]  Y. Novitsky,et al.  Long-term Outcomes of Laparoscopic Resection of Gastric Gastrointestinal Stromal Tumors , 2006, Annals of surgery.

[13]  O. GonzaloMéndez,et al.  Tumores estromales del estómago , 2006 .

[14]  R. DeMatteo,et al.  Gastrointestinal stromal tumor: 5 years later , 2005, Cancer.

[15]  G. Kanel,et al.  Gastrointestinal stromal tumors: Clinical profile, pathogenesis, treatment strategies and prognosis , 2005, Journal of gastroenterology and hepatology.

[16]  B. Nilsson,et al.  Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era , 2005, Cancer.

[17]  Rossella Bertulli,et al.  Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial , 2004, The Lancet.

[18]  E. Gaffney,et al.  Gastrointestinal stromal tumours , 2003, The British journal of surgery.

[19]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[20]  L. Sobin,et al.  Diagnosis of gastrointestinal stromal tumors: A consensus approach. , 2002, Human pathology.

[21]  Takashi Yamada,et al.  CLINICOPATHOLOGIC AND IMMUNOHISTOCHEMICAL STUDY OF GASTROINTESTINAL STROMAL TUMORS (GIST) , 2002 .

[22]  Sigrid Stroobants,et al.  Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study , 2001, The Lancet.

[23]  L. Karnell,et al.  Small Bowel Sarcoma: Analysis of Survival From the National Cancer Data Base , 2001, Annals of Surgical Oncology.

[24]  D. Tuveson,et al.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.

[25]  L. Kindblom,et al.  Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. , 1998, The American journal of pathology.

[26]  M. Miettinen,et al.  Gastrointestinal stromal tumors--value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. , 1995, The American journal of surgical pathology.

[27]  M. Enjoji,et al.  A clinicopathologic and immunohistochemical study of gastrointestinal stromal tumors , 1992, Cancer.

[28]  M. Mazur,et al.  Gastric stromal tumors Reappraisal of histogenesis , 1983, The American journal of surgical pathology.

[29]  S. Nguyen,et al.  Laparoscopic management and longterm outcomes of gastrointestinal stromal tumors. , 2009, Journal of the American College of Surgeons.

[30]  R. DeMatteo,et al.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. , 2000, Annals of surgery.